Global Antiretroviral Therapy Market 2017-2021

抗レトロウイルス療法の世界市場2017-2021

◆タイトル:Global Antiretroviral Therapy Market 2017-2021
◆商品コード:IRTNTR15445
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2017年11月13日
◆ページ数:81
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療・バイオ
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥392,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥448,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥560,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

Technavio社が発行した当調査レポートでは、抗レトロウイルス療法の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、抗レトロウイルス療法の世界市場規模及び予測、薬剤種類別分析、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。Technavio社は抗レトロウイルス療法の世界市場が2017-2021年期間中に年平均2.64%成長すると予測しています。当レポート上に記載されている主な企業は、Gilead、ViiV Healthcare、Janssen Pharmaceuticals、F. Hoffmann-La Roche等です。

About Antiretroviral Therapy
The antiretroviral therapy (ART) market is primarily related to the treatment of human immunodeficiency virus (HIV) infection. Antiretroviral drugs are usually taken in combination to prevent the growth of the virus, which slows the growth of HIV infection. The major drivers for the ART market include the rising awareness of retroviral infection, aggressive innovation in diagnostic techniques, the introduction of novel drugs through significant investments made in R&D, and high unmet needs in the retrovirus infection treatment domain.

Technavio’s analysts forecast the global antiretroviral therapy market to grow at a CAGR of 2.64% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global antiretroviral therapy market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Antiretroviral Therapy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Gilead
• ViiV Healthcare
• Janssen Pharmaceuticals
• F. Hoffmann-La Roche

[Other prominent vendors]
• Abbvie
• Boehringer Ingelheim
• Bionor Pharma
• Vertex Pharmaceuticals
• Mylan

[Market driver]
• Rising awareness of retroviral infection
• For a full, detailed list, view our report

[Market challenge]
• High cost of antiretroviral drugs
• For a full, detailed list, view our report

[Market trend]
• Significant pipeline
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

Table of Contents
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION
• Market outline

PART 05: DISEASE OVERVIEW

PART 06: MARKET LANDSCAPE
• Market overview
• Market size and forecast
• Five forces analysis

PART 07: PIPELINE LANDSCAPE

PART 08: MARKET SEGMENTATION BY DRUG CLASS
• Multiclass combination products
• NRTIs
• Integrase inhibitors
• NNRTIs
• Others

PART 09: REGIONAL LANDSCAPE
• Regional comparison
• ART market in Americas
• ART market in EMEA
• ART market in APAC
• Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges

PART 12: MARKET TRENDS
• Significant pipeline
• Advanced formulations
• Funding and treatment initiatives

PART 13: VENDOR LANDSCAPE
• Vendor landscape

PART 14: KEY VENDOR ANALYSIS
• Gilead
• ViiV Healthcare
• Janssen Pharmaceuticals
• F. Hoffmann-La Roche
• Other prominent vendors

PART 15: APPENDIX
• List of abbreviations

[List of Exhibits]
Exhibit 01: Global ART market
Exhibit 02: Global ART market 2016-2021 ($ millions)
Exhibit 03: Five forces analysis
Exhibit 04: Pipeline landscape by development phase
Exhibit 05: Key clinical trials
Exhibit 06: Global ART market by drug class 2016
Exhibit 07: Global ART market by drug class 2021
Exhibit 08: Global ART market by multiclass combination products 2016-2021 ($ millions)
Exhibit 09: Global ART market by NRTIs 2016-2021 ($ millions)
Exhibit 10: Global ART market by integrase inhibitors 2016-2021 ($ millions)
Exhibit 11: Global ART market by NNRTIs 2016-2021 ($ millions)
Exhibit 12: Global ART market by others 2016-2021 ($ millions)
Exhibit 13: Global ART market: Regional landscape
Exhibit 14: Regional comparison
Exhibit 15: ART market in Americas 2016-2021 ($ millions)
Exhibit 16: ART market in Americas – Year over year growth 2017-2021
Exhibit 17: ART market in EMEA 2016-2021 ($ millions)
Exhibit 18: ART market in EMEA – Year over year growth 2017-2021
Exhibit 19: ART market in APAC 2016-2021 ($ millions)
Exhibit 20: ART market in APAC – Year over year growth 2017-2021
Exhibit 21: Gilead: Key highlights
Exhibit 22: Gilead: Strength assessment
Exhibit 23: Gilead: Strategy assessment
Exhibit 24: Gilead: Opportunity assessment
Exhibit 25: ViiV Healthcare: Key highlights
Exhibit 26: ViiV Healthcare: Strength assessment
Exhibit 27: ViiV Healthcare: Strategy assessment
Exhibit 28: ViiV Healthcare: Opportunity assessment
Exhibit 29: Janssen Pharmaceuticals: Key highlights
Exhibit 30: Janssen Pharmaceuticals: Strength assessment
Exhibit 31: Janssen Pharmaceuticals: Strategy assessment
Exhibit 32: Janssen Pharmaceuticals: Opportunity assessment
Exhibit 33: F. Hoffmann-La Roche: Key highlights
Exhibit 34: F. Hoffmann-La Roche: Strength assessment
Exhibit 35: F. Hoffmann-La Roche: Strategy assessment
Exhibit 36: F. Hoffmann-La Roche: Opportunity assessment



【掲載企業】

Gilead, ViiV Healthcare, Janssen Pharmaceuticals, F. Hoffmann-La Roche, Abbvie, Boehringer Ingelheim, Bionor Pharma, Vertex Pharmaceuticals, and Mylan


【資料のキーワード】

抗レトロウイルス療法

★調査レポート[抗レトロウイルス療法の世界市場2017-2021] (Global Antiretroviral Therapy Market 2017-2021 / IRTNTR15445)販売に関する免責事項
[抗レトロウイルス療法の世界市場2017-2021] (Global Antiretroviral Therapy Market 2017-2021 / IRTNTR15445)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆